STEM CELL TREATMENT
01 March 2019
Cell therapy has been developing for the last 30 years and it shows results in treatment of such pathologies as diabetes, multiple sclerosis, encephalopathies, rheumatic diseases, cardiomyopathy, conditions after a heart attack or stroke, chronic obstructive pulmonary disease, Alzheimer disease, myasthenia gravis, Crohn’s disease, autism, cirrhosis, and many others. Сell products are also used in rejuvenation programs.
At Swiss Medica, we use autologous (own) and allogeneic (donated) mesenchymal and hematopoietic stromal cells, fibroblasts, regulatory T-cells, dendritic cells, bone marrow mononuclear cells and stromal vascular fraction. Most commonly used cell product is based on multipotent mesenchymal stromal cells (MMSCs). As a cell treatment product MMSCs can be transplanted intravenous, intramuscular, into the spinal canal or directly into the damaged area.
Applying only stem cells for some cases may be not enough. Cell therapy works more effectively when combined with other therapeutic methods (detoxification, xenon gas, SWT, etc.) that help decrease inflammation, restore mobility, activate the tissue repair process.
You might have heard about the treatment of diseases with bone marrow transplantation. Today, bone marrow is not the only source of cells for therapy. Cell material is harvesting from peripheral blood, adipose tissue, skin, also placenta and umbilical cord taken after a healthy birth.
In this article we are talking about stem cells therapy, how effective it is and how the procedure is carried out.
How do stem cells work?
In high concentration transplanted MMSCs enhance survival and renewal of healthy tissue cells by activating differentiation of local stem cells, which help to restore lost tissue functions . Stem cells also have immunomodulatory effects and an ability to stimulate the development of neurons as well as new blood vessels .
In the therapy, when stem cells are introduced into a patient’s body, they circulate in the blood system until they are attracted to proteins secreted around inflamed or damaged tissue. Stem cells then rush to that injured area and start producing various growth factors, chemokines (help cells to migrate), and adhesion molecules (regulate cell interactions at the molecular level).
The main therapeutic effect of stem cells is their ability to produce cytokines and growth factors in the intercellular space. These special chemicals are able to activate the regenerative functions of distant cells and promote tissue recovery. This mechanism is called paracrine regulation. Cytokines help block the signals of inflammation in various diseases, including autoimmune processes . An important feature of these signal molecules is that their concentrations may be regulated by inflammation and strictly depend on the stage of tissue regeneration. Using cell products based on stromal cells we can boost the production of cytokines, leading to improved function of the damaged tissue.
What effects are expected?
At Swiss Medica, with the helpful properties of cell therapy we can treat and achieve improvement of diseases of the nervous system, musculoskeletal system, heart, digestive organs, autoimmune system, as well as issues related to age, genetic diseases, and more.
Here are some results of our patients.
Marino from Melbourne, Australia, 41 years old. He was diagnosed with multiple sclerosis. He had problems with balance, vision, feeling in his hands. Medicines were not working. After he had stem cell treatment he felt more energetic, his vision improved, and his General state “is getting better and better”.
Celeste from the USA. Diabetes type 1. Two years ago she underwent treatment with stem cells harvested from her own bone marrow. This gave an increase in her C-peptide level that almost doubled from 0.03 up to <0.05. This indicator shows the level of natural insulin production. After the second therapy with mesenchymal stromal cells, the level of C-peptide rose from 1.15 to 1.9. This means that the patient's body began to produce its own insulin even after 22 years of illness!
A patient from London brought his 77-year-old mother to Swiss Medica for treatment. She suffered from pain in her legs and from heart disease. Therapy with stem cells taken from donated umbilical cord blood was applied. Now the patient says she feels stronger and walks better, and the pain in her joints has been alleviated.
The possible effects of therapy with cell products won’t be the same in all cases, each patient is unique. You can contact a medical Advisor from Swiss Medica to discuss your condition with a specialist of our clinic or you can also leave your contact details for a callback. It is free and confidential.
Types of cell products
Depending on the therapeutic purposes, different cell-based products can be used for different tasks. The doctor will recommend options, which are likely to work in your case. All of our cell products are prepared and cultivated in our own laboratory.
SVF – stromal vascular fraction. SVF contains various stem and progenitor cells, including MMSCs, as well as immune cells (monocytes and macrophages), fibroblasts, pericytes, endothelial progenitor cells and other types of helpful cells that are involved in the regeneration process. For example, tissue-specific progenitor cells are presented in various tissues of the body, they replace the dead cells, thus contributing to the renewal of the cell population and, as a result, to tissue regeneration. SVF can be isolated from lipoaspirate and used as a rapid and safe method for facilitating the healing of chronic wounds, treatment of osteoarthritis, systemic and multiple sclerosis, heart disease, allergy, alopecia, etc. .
Harvesting adipose-derived stem cells is a much easier procedure than a bone marrow extraction.
Lipoaspirate also contains much larger volumes (x2500) of multipotent mesenchymal stromal cells with higher growth capacity and a lower aging rate than stromal cells sourced from bone marrow.
Cultivated MMSCs – multipotent mesenchymal stromal cells. Due to their ability to activate the recovery of damaged tissues they are used in the treatment of a large number of pathologies, including neurodegenerative diseases, diabetes, arthritis and arthrosis, digestive system disorders, arterial hypertension and infarction, pulmonary diseases, obesity, erectile dysfunction, in the recovery after injuries, etc. .
Fibroblasts – dermal cells that are responsible for the skin’s ability to repair and renew. The function of fibroblasts is to produce collagen, elastin, and hyaluronic acid. It’s used in programs designed to correct the external signs of aging.
Other types of cell products. In some cases, hematopoietic stromal cells isolated from the blood of the umbilical cord (treatment of blood diseases), regulatory T-cells (in autoimmune diseases treatment), dendritic cell vaccines and bone marrow mononuclear cells (MNC) can be used.
Own and donated stromal cells
Based on their source, stem cells for treatment are divided into two categories:
- Autologous (donor and recipient are the same) – can be obtained from the patient’s own tissues (adipose tissue, bone marrow, peripheral blood, skin, gingiva).
- Allogeneic (donor is not the patient) – can be obtained from donated tissues (all of the above + placenta and umbilical cord harvested only with the consent of the donor and only as a result of healthy birth).
To achieve the best therapeutic effect, we prescribe donor cells in situations:
- If there are contraindications to anesthesia or a high risk of bleeding in a sampling of the patient’s own biomaterial. When using cell products from donated tissues there is no need to perform an invasive procedure such as adipose-tissue aspiration or bone marrow extraction;
- If the patient’s cells have a low proliferative potential (the ability to reproduce);
- If therapy should be started immediately. There is no need to deliver samples to an outside laboratory and wait days for the cells to be returned for injection – donated cells have already been harvested and are available.
MMSCs do not produce specific proteins that are recognized by the immune system, so they remain “invisible”. Regardless of the source from which they were harvested, stem cells are highly biocompatible and there is no risk of rejection .
Transplantation of MMSCs. How is the procedure carried out?
First, the patient undergoes a full examination to determine the current state of health. Then our specialist makes a conclusion about the appropriateness and expected effects of therapy.
Next, the question is whether self-sourced or donor stem cells will be used. In the first case, the biopsy is performed and stromal cells are isolated from the patient’s own biomaterial. Then the harvested cells are cultivated to the required volume. Usually, this takes 3-4 weeks depending on the proliferative potential of the MMSCs. After that, the cultivated cells can be used for therapy or stored in a cryobank for an unlimited period of time. In the case of donor cells, the cell product can be used immediately in the initial treatment.
The use of cell products is carried out under medical supervision. The volume of cell mass required for treatment is calculated depending on the patient’s body weight. Before use, a test for sterility and infectious/bacteriological safety is carried out. Then a passport of the cell product is drawn up. This passport indicates the name of the cell product, the source of cells, date of extraction, cells characteristics, description of final product formulation, etc.
Routes of administration
When the cell product is ready for use, it can be administered in several ways, depending on the purpose of therapy, the disease, and the patient’s condition:
- IV drip;
- Intrathecal (spinal tap);
- Retrobulbar (in the eye area);
- Locally (cutaneous covering, joint, cavernous bodies of the penis, etc.).
Usually, the procedure of cell product introduction takes very little time. For example, intravenous infusion takes about 30 minutes. For 2 hours after administration, the patient is monitored (pulse, blood pressure, heart rate, BH, diuresis, ECG, O2 saturation). In the case of complaints, deterioration, or the emergence of new clinical symptoms the patient continues treatment in the hospital until he or she feels well.
In General, the treatment procedure can be carried out within 1 day (subject to the use of SVF or allogeneic cells).
What are the indications, contraindications and side effects?
Treatment with cell products is usually appealed in cases where the standard therapy of the underlying disease is not adequately effective or is associated with complications.
Before therapy, it is necessary to exclude contraindications for cell treatment, including:
- Previous bad experience with cell products;
- Any acute infectious disease;
- Cancer or a precancerous condition;
- Stroke or transient ischemic attack in the last 3 months;
- Deviations of some indicators in blood tests;
- Mental disorders and addictions;
- Contraindications to anesthesia and/or high risk of bleeding and/or pathological processes in the area of the proposed biopsy (does not exclude the possibility of using donor cell products);
- Pregnancy and lactation, and some others.
Along with the expected improvements in cell therapy, unwanted side effects are rare and include allergic and pyrogenic posttransfusion reactions (short-term fever), which are both easily managed.
In a majority of cases, it is possible to decline the manifestations of the disease, weaken pain symptoms, and correct the function that was affected. The therapies generally improve the standard of living.
It is important to understand that in order to achieve the best results, an integrated approach is used, where the use of stem cells is only one of the stages. Complex therapy includes various methods that help stem cells during recovery, for example, physiotherapy, reflexotherapy, ultraviolet or laser blood irradiation, oxygen therapy, and other methods.
The medical Advisor of our clinic will tell you if cell-based therapy products can work in your case. For more information, you can contact us online or request a callback from our specialist.
– Published on March 1, 2019 by
Eremin Ilya Igorevich,
Vice Director for Science and Research,
Senior Research Associate at the Laboratory for Cellular Biology and Developmental Pathology at the Institute of General Pathology and Pathophysiology;
Associate Professor of the Department of Regenerative Medicine and Biomedical Technology at A.I. Yevdokimov Moscow State University of Medicine and Dentistry;
Member of the Department of Plastic and Reconstructive Surgery, Cosmetology and Cellular Technologies (Pirogov Russian National Research Medical University);
Member of International Federation for Adipose Therapeutics and Science (IFATS);
Member of International Society of Plastic & Regenerative Surgeons (ISPRES);
Member of Cell Society;
Member of International Placenta Stem Cells Society (IPLASS);
Author and co-author of more than 120 scientific articles, and co-author of 6 patents of invention.
- Pandey A.C., Semon J.A., Kaushal D. et al. MicroRNA profiling reveals age-dependent differential expression of nuclear factor κB and mitogen-activated protein kinase in adipose and bone marrow-derived human mesenchymal stem cells. Stem Cell Research & Therapy 2011;2(6): 49.
- Da Silva J.S., Hare J.M. Cell-based therapies for myocardial repair: emerging role for bone marrow-derived mesenchymal stem cells (MSCs) in the treatment of the chronically injured heart. Methods in Molecular Biology. 2013;1037:145–163.
- Bujak M., Frangogiannis N.G. The role of IL-1 in the pathogenesis of heart disease. Archivum. Immunologiae et Therapiae Experimentalis (Warsz) 2009;57(3):165– 176.
- Concise Review: Fat and Furious: Harnessing the Full Potential of Adipose-Derived Stromal Vascular Fraction. Dykstra J.A., Facile T., Patrick R.J., Francis K.R., Milanovich S., Weimer J.M., Kota D.J.
- Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair—current views. Phinney D.G., Prockop D.J.
- De Miguel M.P., Fuentes-Julian S., Blazquez-Martinez A. et al. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Current Molecular Medicine. 2012; 12(5):574–591.
Patient's results of treatment
at Swiss Medica
Diabetes type 2
And what results can you get from stem cell treatment?
About Swiss Medica clinic
Our primary task is to make your own cells treat your own body. We use advanced technology to activate
mesenchymal stem cells derived from adipose tissue, bone marrow, etc. Donated cells can also
be used. Introduced to the patient’s body, these cells help to regenerate damaged tissue. Symptoms
become less obvious and/or disappear.
*Patient feedback, articles and testimonials provided on this site are for informational purposes
only and should not be considered as a guaranteed result for every case of illness. The treatment
result depends on the disease, patient’s condition, number of treatment procedures, etc.
All form fields are required.